<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0811211281
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZINNAT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUROXIME AXETIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Granules for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO SAUDI ARABIA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 5182]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sandoz Limited Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sandoz Pharmaceuticals d.d
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zinnat belongs to a group of antibiotics called <em>cephalosporins</em>. It works by killing bacteria that cause infections.&nbsp;&nbsp;</p><p>Zinnat is used in adults and children to treat severe infections of the:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ears, nose and throat&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->lungs or chest &nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->urinary tract&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->skin and soft tissues.</p><p>Zinnat is also used to treat:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sexually transmitted infections (gonorrhoea, urethritis and cervicitis)&nbsp;&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Lyme disease (an infection spread by parasites called ticks).</p><p>Your doctor should test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to Zinnat during your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Don&rsquo;t take Zinnat&nbsp;</p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are<strong> allergic </strong><em>(hypersensitive)</em> to antibiotics or any of the other ingredients of Zinnat (<em>listed in section 6</em>).</p><p>&egrave;<strong> </strong>If you think this applies to you,<strong> don&rsquo;t take<em> </em>Zinnat</strong> until you have checked with your doctor.</p><p>Take special care with Zinnat</p><p><strong>Zinnat is not recommended for children aged under 3 months, </strong>as it has not been adequately studied in this age group.</p><p>Look out for important symptoms</p><p>Zinnat can cause serious side effects such as allergic reactions, fungal infections (such as candida) and severe diarrhoea (pseudomembranous colitis).&nbsp; You must look out for certain symptoms while you are taking Zinnat, to reduce the risk of any problems. See &lsquo;<em>Look out for important symptoms&rsquo;</em><strong> in Section 4</strong>.</p><p>While you are taking Zinnat</p><p>If you need a blood test&nbsp;</p><p>Zinnat can affect the results of a test for blood sugar levels, or a blood screen called the Coombs test. If you need a blood test:<strong> </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave; &nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell the person taking the sample </strong>that you have taken Zinnat.<strong> </strong></p><p>Other medicines and Zinnat&nbsp;</p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones.&nbsp; This includes medicines bought without a prescription.</p><p>Medicines used to <strong>reduce the amount of acid in your stomach </strong>(e.g. <em>antacids</em> used to treat <strong>heartburn</strong>)<strong> </strong>can affect how Zinnat works.&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave; &nbsp;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist</strong> if you are taking any medicine like this.</p><p>Contraceptive pill</p><p>Zinnat may reduce how well the contraceptive pill works. If you are taking the contraceptive pill while you are being treated with Zinnat you also need to use a<strong> barrier method of contraception</strong> (such as condoms). Ask your doctor for advice.</p><p>Pregnancy and breast-feeding</p><p>There is only limited information about the safety of Zinnat in pregnant women.<strong> If you are pregnant</strong> your doctor will discuss with you if the benefits of taking Zinnat outweigh the possible risks to your baby.&nbsp;</p><p>The ingredients in Zinnat can pass into breast milk.&nbsp; <strong>If you are breast-feeding, you must check with your doctor</strong> before you take Zinnat.</p><p>Driving and using machines</p><p><strong>Zinnat can make you dizzy</strong> and have other side effects that make you less alert.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave; &nbsp;&nbsp;&nbsp; <strong>Don&rsquo;t drive or use machines</strong> unless you&rsquo;re feeling well.</p><p>Zinnat contains sugar and aspartame</p><p><strong>Zinnat</strong> suspension contains sugar. If you are diabetic you need to take this into account for your diet.</p><p><strong>Zinnat</strong> suspension also contains <strong>aspartame</strong>, which is a source of phenylalanine. If you have an intolerance to aspartame or have a condition called <strong>phenylketonuria (PKU)</strong>:<strong> </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave;<strong> &nbsp;&nbsp;&nbsp; Check with your doctor </strong>that <strong>Zinnat</strong> is suitable for you.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>How much to take&nbsp;</p><p><strong>Always take Zinnat exactly as your doctor has told you to.</strong> Check with your doctor or pharmacist if you&#39;re not sure.</p><p>If you have kidney problems your doctor may reduce your dose.</p><p>Adults</p><p>The usual dose of <strong>Zinnat</strong> is 125 mg to 1 g per day depending on the severity and type of infection.</p><p>Children</p><p>Your doctor will decide on the correct dose of&nbsp; <strong>Zinnat</strong> for your child depending on: &bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the severity and type of infection</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the weight and age of the child.</p><p><strong>Zinnat is not recommended for children aged under 3 months</strong>, as it has not been adequately studied in this age group.</p><p>Depending on the illness or how you or your child responds to treatment, the starting dose may be changed or more than one course of treatment may be needed.</p><p>How to take/use</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Take Zinnat suspension after food. This will help to make the treatment more effective.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Shake the bottle before use.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Zinnat suspension can be diluted in cold fruit juices, or milk drinks but should be taken immediately after mixing.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Don&rsquo;t mix Zinnat with hot liquids.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For children who can&rsquo;t take Zinnat using a spoon, a dosing syringe with a 5 ml graduation is supplied with the pack so you can measure your child&rsquo;s dose accurately.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->For step-by-step instructions on how to make up Zinnat suspension <strong>see section 7</strong>.</p><p>If you forget to take Zinnat&nbsp;</p><p><strong>Don&#39;t take an extra dose to make up for a missed dose</strong>. Just take your next dose at the usual time.</p><p>If you take too much Zinnat</p><p>If you take<em> </em>too much<em> </em>Zinnat you may be <strong>more likely to have fits<em> </em></strong><em>(seizures)<strong>.</strong></em></p><p>&egrave; &nbsp;&nbsp;&nbsp;&nbsp; <strong>Don&#39;t delay.</strong> <strong>Contact your doctor or your nearest hospital emergency department immediately</strong>. If possible, show them the Zinnat pack.</p><p>Don&rsquo;t stop Zinnat without advice</p><p><strong>It is important that you take the full course of Zinnat</strong>.&nbsp; Don&rsquo;t<strong> </strong>stop unless your doctor advises<strong> </strong>you to &ndash; even if you are feeling<strong> </strong>better. If you don&#39;t complete<strong> </strong>the full course of treatment, the<strong> </strong>infection may come back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zinnat can cause side effects, but not everybody gets them.</p><p>Look out for important symptoms</p><p>Severe allergic reactions</p><p>These are very rare in people taking Zinnat. Signs include:</p><p><!--[if !supportLists]-->&Yuml;&nbsp; <!--[endif]-->raised and itchy rash (hives)</p><p><!--[if !supportLists]-->&Yuml;&nbsp; <!--[endif]-->swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing &Yuml;<strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>collapse.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave;<strong> &nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor immediately</strong> if you get any of these symptoms.</p><p>Serious skin reactions</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) <em>erythema multiforme</em></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->a widespread rash with blisters and skin peeling on much of the body surface<em> (toxic epidermal necrolysis)</em>, particularly around the mouth, nose, eyes and genitals (<em>StevensJohnson syndrome</em>).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave; &nbsp;&nbsp;&nbsp; <strong>Contact a doctor immediately</strong> if you get these symptoms.</p><p>Fungal infections</p><p>On rare occasions, medicines like Zinnat can cause an overgrowth of yeast (<em>Candida</em>) in the body which can lead to fungal infections (such as thrush). This side effect is more likely if you take Zinnat for a long time.</p><p>&egrave;<strong> &nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor as soon as possible</strong> if you think you have a fungal infection. Your doctor may need to stop your treatment.</p><p>Severe diarrhoea (Pseudomembranous colitis)</p><p>On rare occasions, medicines like Zinnat can cause inflammation of the colon (large intestine), causing diarrhoea, usually with blood and mucus, stomach pain, fever. &egrave;<strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor as soon as possible </strong>if you get any of these symptoms.<strong> </strong></p><p>Jarisch-Herxheimer reaction</p><p>Some patients may get a high temperature (fever), chills, headache, muscle pain and skin rash while being treated with Zinnat for Lyme Disease. This is known as the <em>Jarisch-Herxheimer reaction.</em> Symptoms usually last a few hours or up to one day.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &egrave; &nbsp;&nbsp;&nbsp; <strong>Tell your doctor immediately </strong>if you get any of these symptoms.<strong> </strong></p><p>Common side effects</p><p>These may affect up to 1 in 10 people:&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->fungal infections (such as candida)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->headache</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->dizziness</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->diarrhoea</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->nausea (feeling sick)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->stomach pain.</p><p><strong>Common side effects that may show up in blood tests: </strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increase in a type of white blood cell (<em>eosinophilia</em>)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->increase in some substances (<em>enzymes</em>) produced by the liver.</p><p>Uncommon side effects</p><p>These may affect <strong>up to 1 in 100</strong> people:&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->vomiting</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->skin rashes.</p><p><strong>Uncommon side effects that may show up in blood tests: </strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->decrease in number of blood platelets (cells that help blood to clot) called <em>thrombocytopenia </em></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->decrease in the number of white blood cells (<em>leukopenia</em>).</p><p>Rare side effects</p><p>These may affect <strong>up to 1 in 1,000</strong> people:&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe diarrhoea (pseudomembranous colitis).</p><p>Very rare side effects</p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->allergic reactions</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe skin reactions</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->high temperature (<em>fever</em>)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->yellowing of the whites of the eyes or skin (<em>jaundice</em>) &bull; &nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>).</p><p><strong>Very rare side effects that may show up in blood tests: </strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->red blood cells destroyed too quickly (<em>haemolytic anaemia</em>).</p><p>If you get side effects</p><p>&egrave; &nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.&nbsp;</p><p>Do not take Zinnat after the expiry date shown on the pack.</p><p><!--[if !supportLists]-->6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Do not store Zinnat granules above 30&deg;C.</p><p><!--[if !supportLists]-->7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Once mixed with the correct amount of water, Zinnat suspension, must be stored in the fridge between 2&deg;C and 8 C.</p><p><!--[if !supportLists]-->8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Throw away the bottle 10 days after first opening it, but don&rsquo;t dispose of the medicine in your waste water or your household rubbish.&nbsp; Ask your pharmacist how to dispose of medicines no longer required.&nbsp; This will help to protect the environment.<em>&nbsp; </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cefuroxime axetil.</p><p>Each 5 ml of solution contains either 125 mg or 250 mg cefuroxime axetil when mixed with the correct amount of water.</p><p>The other ingredients are:</p><p><strong>List of Excipients </strong></p><p><u>Aspartame.</u></p><p>Xantham gum.</p><p>Acesulfame potassium.</p><p>Povidone K30.</p><p>Stearic acid.</p><p>Sucrose.</p><p>Tutti frutti flavour.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Sucrose Quantities: </strong></p><table cellspacing="0" cellpadding="0" border="0" style="width:232.2pt"><tbody><tr><td colspan="2" style="border-color:black; height:26.5pt; vertical-align:top; width:232.2pt"><p>Sucrose quantity (g per dose)</p></td></tr><tr><td style="border-color:black; height:40.3pt; vertical-align:top; width:1.65in"><p>125mg/5ml</p><p>Suspension</p></td><td style="height:40.3pt; vertical-align:top; width:113.4pt"><p>250mg/5ml</p><p>Suspension</p></td></tr><tr><td style="border-color:black; height:26.65pt; vertical-align:top; width:1.65in"><p>3.062g</p></td><td style="height:26.65pt; vertical-align:top; width:113.4pt"><p>2.289g</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zinnat comes as granules for concentrate for solution. The granules provide 125 mg or 250 mg per 5 ml of active substance when reconstituted as recommended. 
Not all pack sizes are marketed in every country. 

7. Step-by-step instruction  

Directions for making up the suspension: 
1.	Shake the bottle to loosen the granules and remove the cap  
2.	Add the amount of water stated on the bottle label and replace the cap. 
3.	Turn the bottle upside down and rock vigorously (for at least 15 seconds) as shown below. 
  
 
4.	Turn the bottle the right way up and shake vigorously. 
5.	<Tradename> suspension, must be stored in the fridge between 2 °C and 8 °C 
	 	 Directions for using the dosing syringe: 
1.	If you are using a dosing syringe, allow the suspension to stand for at least one hour before taking the first dose. 
2.	Remove the bottle cap and push the bung firmly into the top of the bottle.  
3.	Push the dosing syringe firmly into the top of the bung. 
4.	Turn the bottle upside down. 
5.	Pull the plunger of the syringe back so that the medicine is drawn from the bottle into the syringe. Pull the plunger back to the point on the scale that corresponds to the dose prescribed for your child. 
	Contact your doctor or pharmacist if you are at all confused about how much medicine to draw into the syringe. 
6.	Turn the bottle back the right way up and carefully remove the syringe from the bung, holding it by the barrel rather than the plunger. 
7.	Gently put the tip of the syringe into the child's mouth, to the inside of the child's cheek. 
8.	Slowly and gently push the plunger down to gently squirt the medicine into the inside of your child's cheek. Allow them to swallow it.  
	Don’t forcefully push down the plunger, or squirt the medicine to the back of your child's mouth or throat, as the child may choke. 
9.	Remove the syringe from your child's mouth. 
10.	Remove the bung and replace the lid on the bottle. 
11.	Rinse the bung and syringe in warm water and leave to dry. 
12.	Repeat the above for each dose as instructed by your doctor or pharmacist 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder&nbsp; </strong></p><p>Glaxo Saudi Arabia Ltd.*</p><p><strong>Manufactured by: </strong></p><p>Glaxo Operations UK Limited (trading as Glaxo Wellcome operations)</p><p><strong>Packed by: </strong></p><p><strong>Glaxo Saudi Arabia Ltd.* </strong></p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number GDS: 25 
Version Date: 06 JULY 2014 

ZINNAT is a registered trademark of the GlaxoSmithKline group of companies 
© 2015 GlaxoSmithKline, all rights reserved 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ینتمي زینات إلى مجموعة من المضادات الحیویة تُعرف باسم سیفالوسبورین، والتي تعمل على قتل الجراثیم التي تسبب العدوى.&nbsp;</p><p>ویستخدم الأطباء زینات لعلاج البالغین والأطفال الذین یعانون من العدوى الحادة التي تصیب:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأذن والأنف والحنجرة&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الرئتین أو الصدر&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المسالك البولیة&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البشرة والأنسجة الرخوة.</p><p><strong>كما یستخدم الأطباء زینات في علاج: </strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العدوى المنقولة جنسیًا (السیلان والتھاب الإحلیل والتھاب عنق الرحم)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->داء لایم (أحد أنواع العدوى التي تنتشر بسبب طفیلیات تُعرف باسم القراد).</p><p>ینبغي أن یختبر الطبیب نوع الجراثیم التي تسبب العدوى وأن یراقب مدى حساسیة الجراثیم تجاه زینات خلال فترة العلاج.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا یجوز تناول زینات في الحالات التالیة </strong>&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعاني من <strong>الحساسیة</strong> (فرط الحساسیة) تجاه المضادات الحیویة أو غیرھا من مكونات زینات (المذكورة في القسم رقم <em>6</em>).</p><p>&larr; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تظن أن ھذه الأمر ینطبق على حالتك،<strong> فلا یجوز </strong>تناول <strong>زینات</strong> إلا بعد استشارة الطبیب.</p><p><strong>ینبغي توخي الحذر عند تناول زینات</strong></p><p><strong>لا یوصي الأطباء بوصف زینات للأطفال ممن تقل أعمارھم عن </strong><strong>3</strong> أشھر، حیث لم یخضع للدراسات المناسبة حول تأثیره على ھذه الفئة العمریة.</p><p><strong>احترس بشأن الأعراض الخطیرة</strong></p><p>یمكن أن یؤدي دواء زینات إلى حدوث آثار جانبیة خطیرة مثل تفاعلات الحساسیة والعدوى الفطریة (مثل المبّیّضة) والإسھال الحاد (التھاب القولون الغشائي الكاذب). ویجب الانتباه بشدة تجاه ظھور بعض الأعراض أثناء تناول زینات ،انتباھًا یقلل من مخاطر التعّرّض للمشكلات. انظر &quot; احترس بشأن الأعراض الخطیرة&quot; <strong>في القسم رقم</strong> <strong>4</strong>.</p><p><strong>أثناء تناول دواء زینات </strong></p><p><strong>إذا كنت تحتاج لإجراء اختبار دم&nbsp; </strong></p><p>فقد یؤثر زینات على نتائج اختبارات معرفة مستویات السكر في الدم أو فحص الدم المعروف باسم اختبار كومس. <strong>إذا كنت تحتاج لإجراء اختبار دم: </strong></p><p>&larr; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فینبغي<strong> إخبار اختصاصي أخذ العینة </strong>أنك تناولت زینات.<strong> </strong></p><p><strong>علاقة زینات بالأدویة الأخرى </strong>&nbsp;</p><p><strong>ینبغي إخبار الطبیب أو الصیدلي إذا كنت تتناول أدویة أخرى</strong>، أو تناولتھا مؤخرًا، أو إذا بدأت تناول أدویة جدیدة.</p><p>ویشتمل ذلك على الأدویة التي یمكن شراؤھا دون وصفة طبیة.</p><p>یمكن أن تؤثر الأدویة التي تتناولھا لتقلیل مقدار الأحماض في المعدة (مثل مضادات الحموضة التي یتناولھا المریض لعلاج حرقة المعدة) على التأثیر العلاجي لزینات.&nbsp;</p><p>&larr;<strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ینبغي إخبار الطبیب أو الصیدلي</strong> إذا كنت تتناول أدویة مثل المذكورة.</p><p><strong>أقراص منع الحمل</strong></p><p>یمكن أن یؤثر زینات على كفاءة التأثیر العلاجي لأقراص منع الحمل. إذا كنتِ تتناولین أقراص منع الحمل أثناء تناول زینات فینبغي استخدام<strong> وسیلة أخرى لمنع الحمل أیضًا</strong> (مثل الواقي الذكري). وینبغي استشارة الطبیبة.</p><p><strong>الحمل والرضاعة الطبیعیة</strong></p><p>لا تتوفر غیر معلومات محدودة حول سلامة زینات عند استخدامھ لعلاج النساء الحوامل. إذا&nbsp; كنتِ<strong> حاملا ً</strong> فسوف <strong>تناقشك الطبیبة </strong>بشأن فوائد تناول زینات مقارنة بالمخاطر المحتملة التي قد تھدد الجنین.&nbsp;</p><p>كما ینغي إدارك أن مكّوّنات زینات یمكن أن تنتقل إلى الطفل عبر الرضاعة الطبیعیة. <strong>إذا كنِتِ تُرضعین رضاعة طبیعیة ،فیجب علیِكِ استشارة الطبیبة</strong> قبل تناول زینات.</p><p><strong>أثر تناول الدواء على القیادة واستخدم الآلات</strong></p><p><strong>یمكن أن یتسبب زینات في شعور المریض بالدوار</strong> والتعّرّض للآثار الجانبیة الأخرى التي تقلل من انتباھھ.</p><p>&larr;<strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلا تجوز القیادة ولا استخدام الآلات</strong> إلا إذا كنت تشعر بحالة جیدة.</p><p><strong>یحتوي</strong> زینات على السكر والأسبارتام<strong> </strong></p><p>یحتوي زینات المعلق على السكر. فإذا كنت مریضًا بالداء السكري فینبغي الانتباه لھذا الأمر عند مراعاة النظام الغذائي.</p><p>یحتوي معلق <strong>زینات</strong> أیضًا على الأسبارتام والذي یُعد أحد مصادر الفینیل ألانین. فإذا كنت تعاني من عدم تحمل<strong> الأسبارتام أو </strong>كنت تعاني من مرض <strong>بیلة الفینیل كیتون</strong> <strong>(PKU)</strong>:<strong> </strong></p><p>&larr;<strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فینبغي استشارة الطبیب </strong>للتأكد من أن <strong>زینات</strong> یتناسب مع حالتك.<strong> </strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>مقدار الجرعة </strong>&nbsp;</p><p><strong>ینبغي تناول زینات وفق الجرعة التي یحددھا الطبیب.</strong> وإذا شككت في الجرعة المحددة فینبغي استشارة الطبیب أو الصیدلي.</p><p>إذا كنت تعاني من مشكلات بالكلى فربما یلجأ الطبیب إلى تقلیل الجرعة.</p><p><strong>البالغون</strong></p><p><strong>تتراوح الجرعة الیومیة العادیة </strong>من <strong>زینات</strong> بین 125 ملغم و 1 غرام بحسب خطورة العدوى ونوعھا.</p><p><strong>الأطفال</strong></p><p>سوف یحدد الطبیب الجرعة المناسبة للطفل من <strong>زینات</strong> بحسب:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حدة العدوى ونوعھا</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وزن الطفل وعمره.</p><p><strong>لا یوصي الأطباء بوصف زینات للأطفال ممن تقل أعمارھم عن </strong><strong>3</strong> أشھر، حیث لم یخضع للدراسات المناسبة حول تأثیره على ھذه الفئة العمریة.<strong> </strong></p><p>بحسب المرض أو طبیعة استجابتك أنت أو الطفل للعلاج، یجوز تغییر الجرعة الأولیة أو ربما یحتاج المریض لأكثر من مسار علاجي واحد.</p><p><strong>طریقة تناول زینات</strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ینصح الأطباء بتناول معلق زینات بعد تناول الطعام. فھذا الإجراء یساعد على جعل العلاج أكثر فاعلیة.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ینبغي رّجّ الزجاجة جیدًا قبل الاستخدام.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->یمكن تخفیف معلق زینات باستخدام عصائر الفواكھ الباردة أو المشروبات التي تحتوي على اللبن ولكن ینبغي تناولھا فور المزج.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لا یجوز خلط زینات بالسوائل الساخنة.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->وأما الأطفال الذین یتعذر علیھم تناول زینات بواسطة الملعقة، فتتوفر من أجلھم محقنة لتحدید الجرعات مدّرّجة قیاس 5 ملیلتر مع العبوة حتى یتسنى قیاس جرعة الطفل بدقة.</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->للحصول على التعلیمات خطوة بخطوة حول كیفیة إعداد معلق زینات انظر <strong>القسم رقم</strong> <strong>7</strong>.</p><p><strong>عند نسیان جرعة من زینات </strong>&nbsp;</p><p><strong>لا یجوز تناول </strong>جرعة إضافیة<strong> لتعویض الجرعة الفائتة</strong>. فما علیك سوى تناول الجرعة التالیة في موعدھا المحدد.</p><p><strong>عند تناول جرعة زائدة من زینات</strong></p><p>عند تناول جرعة زائدة من زینات فیترجح <strong>أن تصاب </strong>بنوبات (نوبات مرضیة).</p><p>&larr;<strong> لا یجوز التأخیر.</strong> <strong>ینبغي الاتصال بالطبیب أو الاتصال بقسم الطوارئ بأقرب مستشفى على الفور</strong>. وإذا أمكن فینبغي إطلاعھم على عبوة زینات.</p><p><strong>لا یجوز إیقاف تناول زینات دون استشارة الطبیب</strong></p><p><strong>من الأھمیة إتمام المسار العلاجي الكامل بالزینات</strong>. فلا یجوز<strong> </strong>التوقف عن تناولھ إلا وفق استشارة الطبیب<strong> </strong>ولو كنت<strong> </strong>تشعر بتحسن. إذا لم تكمل المسار العلاجي بالكامل، فربما<strong> </strong>تظھر العدوى مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>أسوة بجمیع الأدویة الأخرى، یمكن أن یؤدي زینات إلى الآثار الجانبیة، ولكن لا یُصاب بھا كل المرضى.</p><p><strong>احترس بشأن الأعراض الخطیرة</strong> <strong>تفاعلات الحساسیة الحادة</strong></p><p>یندر أن یُصاب بھا المرضى الذین یتناولون زینات. تتضمن العلامات:</p><p><!--[if !supportLists]-->&Yuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ظھور طفح جلدي بارز مصحوبًا بالوخز (الشرى)</p><p><!--[if !supportLists]-->&Yuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->في بعض الأحیان توّرّم الوجھ أو الفم (وذمة وعائیة) مما یؤدي إلى صعوبة التنفس</p><p><!--[if !supportLists]-->&Yuml;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تدھور الحالة الصحیة.</p><p>&larr;&nbsp; <strong>&nbsp;ینبغي الاتصال بالطبیب على الفور إذا أصابتك ھذه الأعراض.</strong></p><p><strong>التفاعلات الخطیرة بالبشرة </strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الطفح الجلدي الذي قد یتقّرّح ویشبھ الأجزاء الناتئة الصغیرة (بقع سوداء مركزیة مُحاطة بمساحة شاحبة، مع وجود حلقة داكنة حول الأطراف) حمامى متعددة الأشكال</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح واسع الانتشار مصاحب بتقّرّح وتقشیر الجلد یظھر بمعظم سطح الجسم (تقشّر الأنسجة المتموتة البشرویة التسممي)، خاصةً حول الفم والأنف والعیون والأعضاء التناسلیة (متلازمة جونسون ستیفنز).</p><p>&nbsp;&nbsp;&nbsp; &larr;<strong> &nbsp;&nbsp;&nbsp; ینبغي الاتصال بالطبیب على الفور</strong> إذا أصابتك ھذه الأعراض.</p><p><strong>العدوى الفطریة</strong></p><p>في حالات نادرة یمكن للأدویة مثل زینات أن تتسبب في حدوث زیادة نمو للفطریات التي تُعرف باسم (المبّیّضة) في الجسم مما قد یؤدي إلى عدوى فطریة (مثل القلاع). وتترجح الإصابة بھذا الأثر الجانبي عند تناول زینات لفترات طویلة.</p><p>&larr;&nbsp;&nbsp; <strong>ینبغي إخبار الطبیب بأسرع ما یمكن</strong> إذا كنت تظن أنك أصُبت بالعدوى الفطریة. وقد یضطر الطبیب إلى إیقاف العلاج.</p><p><strong>الإسھال الحاد (التھاب القولون الغشائي الكاذب)</strong></p><p>في بعض الأحیان یمكن للأدویة مثل زینات التسبب في حدوث التھاب بالقولون (الأمعاء الغلیظة)، مسببًا الإسھال والذي یكون عادة مُصاحبًا بالدم والمخاط. وألم المعدة والحمى</p><p>&larr;&nbsp;&nbsp; <strong>ینبغي إخبار الطبیب بأسرع ما یمكن إذا أصُبت بھذه الأعراض. </strong></p><p><strong>تفاعل یاریش ھیكسھایمر</strong></p><p>قد یُصاب بعض المرضى بارتفاع درجة الحرارة (الحمى) والقشعریرة والصداع وألم العضلات والطفح الجلدي أثناء العلاج بزینات من داء لایم. ویُعرف ھذا باسم<strong> </strong>&nbsp;<strong>تفاعل یاریش</strong> ھیكسھایمر. وتستمر الأعراض عادةً لبضع ساعات وربما تستمر یومًا. &nbsp;</p><p>&larr;&nbsp;&nbsp; <strong>ینبغي إخبار الطبیب على الفور إذا أصابتك ھذه الأعراض. </strong></p><p><strong>الآثار الجانبیة الشائعة</strong></p><p>یمكن أن تؤثر ھذه الآثار الجانبیة الشائعة على مریض 1 <strong>من بین كل</strong> 10 مرضى:&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->العدوى الفطریة (مثل المبّیّضة)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الصداع</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الدوار</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإسھال</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الغثیان (الشعور بالمرض)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم المعدة.</p><p><strong>الآثار الجانبیة الشائعة التي تظھر في اختبارات الدم:</strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زیادة خلایا الدم البیضاء (كثرة الیوزینیات)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زیادة بعض المواد (الإنزیمیة) التي یفرزھا الكبد.</p><p><strong>الآثار الجانبیة غیر الشائعة</strong></p><p>یمكن أن تؤثر ھذه الآثار الجانبیة غیر الشائعة على مریض <strong>1</strong> <strong>من بین كل</strong> <strong>100</strong> مریض:&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->القيء</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الطفح الجلدي.</p><p><strong>الآثار الجانبیة غیر الشائعة التي تظھر في اختبارات الدم:</strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض عدد الصفائح الدمویة (الصفائح التي تساعد الدم على التجلط) والذي یسمى قلة الصفیحات<em> </em></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->انخفاض عدد خلایا الدم البیضاء (نقص الكُرّیّات البیضاء)</p><p><strong>الآثار الجانبیة النادرة</strong></p><p>یمكن أن تؤثر ھذه الآثار الجانبیة غیر الشائعة على مریض <strong>1</strong> <strong>من بین كل</strong> <strong>1</strong><strong>,</strong><strong>000</strong> مریض:&nbsp;</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإسھال الحاد (التھاب القولون الغشائي الكاذب).</p><p><strong>الآثار الجانبیة النادرة جدًا</strong> یمكن أن تؤثر ھذه الآثار الجانبیة غیر الشائعة على مریض <strong>1</strong> <strong>من بین كل</strong> <strong>10</strong><strong>,</strong><strong>000</strong> مریض:</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تفاعلات الحساسیة</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التفاعلات الخطیرة بالبشرة</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ارتفاع درجة الحرارة (الحمى)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->اصفرار بیاض العیون والبشرة (الصفرة)</p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التھاب الكبد الوبائي.</p><p>الآثار الجانبیة النادرة جدًا التي تظھر في اختبارات الدم:<strong> </strong></p><p><!--[if !supportLists]-->&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تلف خلایا الدم الحمراء بسرعة شدیدة (فقر الدم الانحلالي).</p><p><strong>في حالة الإصابة بالآثار الجانبیة</strong></p><p>&larr;&nbsp;&nbsp; ینبغي إخبار الطبیب أو الصیدلي إذا زادت حدة أي أثر جانبي من الآثار الجانبیة المذكورة أو أصبح شدید الإزعاج أو إذا لاحظت آثار جانبیة غیر مذكورة في ھذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یجب حفظ الدواء بعیدًا عن متناول ونظر الأطفال.&nbsp;</p><p>لا یجوز تناول زینات بعد تاریخ انتھاء الصلاحیة المدّوّن على العبوة.</p><p>۱. لا یجوز تخزین حبیبات زینات في درجة حرارة أكثر من 30 درجة مئویة.</p><p>۲. بمجرد خلط زینات بمقدار الماء الصحیح، یجب وضع معلق زینات في الثلاجة على درجة حرارة بین 2 و8 درجات مئویة.</p><p>۳. یجب التخلص من الزجاجة بعد مرور 10 أیام من فتحھا للمرة الأولى ولكن دون التخلص من الدواء بإلقائھ في میاه الصرف ولا المخلفات المنزلیة. ویمكن سؤال الصیدلي حول كیفیة التخلص من الأدویة غیر اللازمة. فتنفیذ ھذه التعلیمات من شأنھ أن یحافظ على البیئة. <em>&nbsp;</em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>مكوّنات زینات</strong></p><p>تتكون المادة الفّعّالة من سیفوروكسیم أكسیتیل.</p><p>وكل 5 ملیلتر من المحلول تحتوي على إما 125 ملغم أو 250 ملغم من سیفوروكسیم أكسیتیل عند خلطھ بالمقدار المناسب من الماء.</p><p>المكونات الأخرى تشمل:</p><p><strong>قائمة السواغات</strong> <u>الأسبارتام.</u></p><p>صمغ الزانثان.</p><p>أسیسلفام البوتاسیوم.</p><p>بوفیدون K30.</p><p>حمض الإستیاریك.</p><p>سكروز.</p><p>نكھة تشكیلیة من الفواكھ.</p><p><img src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>یتوفر زینات على ھیئة حبیبات مركزة لصناعة المحلول. وتعطي الحبیبات 125 ملغم أو 250 ملغم لكل 5 ملغم من المادة الفّعّالة عند تركیبھا وفق الطریقة الموصى بھا. لا تتوفر كل أحجام العبوات في كل الدول. . تعلیمات خطوة بخطوة إرشادات إعداد المعلق: 1. رّجّ الزجاجة لتحریر الحبیبات وانزع الغطاء 2. أضف كمیة الماء المذكورة على ملصق البیانات على الزجاجة وأعد وضع الغطاء. 3. اقلب الزجاجة من الأعلى إلى الأسفل ورّجّھا بقوة (لمدة 15 ثانیة على الأقل) كما ھو موضح أدناه. 4. أعد وضع الزجاجة في الوضع إلى أعلى ثم رّجّھا رجًا قویًا. 5. یجب تخزین معلق &gt;الاسم التجاري&lt; في الثلاجة على درجة حرارة بین 2 و8 درجات مئویة إرشادات استخدام محقنة تحدید الجرعات: 1. في حالة استخدام محقنة تحدید الجرعات ،فینبغي ترك المعلق حتى یثبت تركیبھ لساعة على الأقل قبل تناول الجرعة الأولى. 2. انزع الغطاء واضغط على السدادة الموجودة بطرف الزجاجة العلوي بإحكام. 3. ضع محقنة تحدید الجرعات في السدادة الموجودة بطرف الزجاجة العلوي بإحكام. 4. اقلب الزجاجة من أعلى إلى أسفل. 5. اسحب كابس المحقنة إلى الخلف حتى یُسحب الدواء من الزجاجة إلى داخل المحقنة. اسحب الكابس للخلف إلى النقطة الموجودة على المقیاس التي تتناسب مع الجرعة الموصوفة للطفل. &larr; اتصل بالطبیب أو الصیدلي في حالة الارتیاب بشأن مقدار الدواء الذي سحبتھ إلى داخل المحقنة. 6. أعد الزجاجة إلى الوضع القائم الصحیح واسحب المحقنة بعنایة من السدادة مع إمساكھا من الأنبوب دون الكابس. 7. ضع طرف المحقنة برفق في فم الطفل إلى العمق الذي یتساوى مع وجنتي الطفل. 8. اضغط على الكابس برفق وببطء متوجھًا إلى الأسفل دافعًا الدواء برفق إلى داخل فم الطفل. انتظر حتى یتمكن الطفل من بلع الدواء. &larr; تجنب دفع المحقنة بقوة أو دفع الدواء إلى مؤخرة فم الطفل أو حلقھ حتى لا یتعرض الطفل للاختناق. 9. أخرج المحقنة خارج فم الطفل. 10 انزع السدادة وأعد تركیب الغطاء على الزجاجة. 11 ینبغي شطف السدادة والمحقنة باستخدام الماء الدافئ وتركھا حتى تجف. 12 ینبغي تكرار الخطوات السابقة عند إعطاء كل جرعة وفق تعلیمات الطبیب أو الصیدلي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل التصریح بالتسویق&nbsp; </strong></p><p><strong>Glaxo Saudi Arabia Ltd.*</strong></p><p><strong>جھة التصنیع: </strong></p><p>&nbsp;(Glaxo Wellcome التي تمارس الأنشطة التجاریة باسم عملیات) Glaxo Operations UK Limited</p><p><strong>جھة التعبئة: </strong></p><p><strong>&nbsp;Glaxo Saudi Arabia Ltd.*</strong></p><p>GlaxoSmithKline إحدى شركات*</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاریخ الإصدار بحسب نظام التوزیع العالمي: 25 
تاریخ الإصدار: 6 یولیو 2014 
زینات علامة تجاریة مسّجّلة لصالح مجموعة شركات GlaxoSmithKline 
حقوق النشر والتألیف © لعام 2015 محفوظة لصالح شركة GlaxoSmithKline، وكل الحقوق محفوظة. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zinnat 125mg/5ml granules for oral suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                125 mg cefuroxime per 5 ml (as 150 mg cefuroxime axetil)

Excipient(s) with known effect:

Contains 0.021 g aspartame (E951) per 5 ml dose
Contains 3.1 g of sucrose per 5 ml dose

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dry, white to off-white, tutti-frutti flavoured granules for oral suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t75"
  coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
  filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_66" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:464.6pt;
  margin-top:15.2pt;width:57.9pt;height:50.25pt;z-index:251658240;visibility:visible;
  mso-wrap-style:square;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
  mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:page'
  o:allowoverlap="f">
  <v:imagedata src="file:///C:/Users/hma93774/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page" anchory="page"/>
 </v:shape><![endif]--><!--[if !vml]--></p><p>Zinnat is indicated for the treatment of the infections listed below in adults and children from the age of 3 months (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute streptococcal tonsillitis and pharyngitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial sinusitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute otitis media.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute exacerbations of chronic bronchitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cystitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyelonephritis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncomplicated skin and soft tissue infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of early Lyme disease.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The usual course of therapy is seven days (may range from five to ten days).</p><p><u>&nbsp;</u></p><p><em>Table 1. Adults and children (</em><em>&sup3;</em><em>40 kg)</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute tonsillitis and pharyngitis, acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>250&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Acute otitis media</p></td><td style="vertical-align:top"><p>500 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Acute exacerbations of chronic bronchitis</p></td><td style="vertical-align:top"><p>500&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis</p></td><td style="vertical-align:top"><p>250&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Lyme disease</p></td><td style="vertical-align:top"><p>500&nbsp;mg twice daily for 14 days (range of 10 to 21 days)</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em>Table 2. Children (&lt;40 kg)</em></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute tonsillitis and pharyngitis, acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>10 mg/kg twice daily to a maximum of 125 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Children aged two years or older with otitis media or, where appropriate, with more severe infections</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250&nbsp;mg twice daily for 10 to 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Lyme disease</p></td><td style="vertical-align:top"><p>15 mg/kg twice daily to a maximum of 250&nbsp;mg twice daily for 14 days (10 to 21 days)</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p>There is no experience of using Zinnat in children under the age of 3 months.</p><p>&nbsp;</p><p>Cefuroxime axetil tablets and cefuroxime axetil granules for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see section 5.2).</p><p>&nbsp;</p><p>In infants (from the age of 3 months) and children with a body mass of less than 40 kg, it may be preferable to adjust dosage according to weight or age. The dose in infants and children 3&nbsp;months to 18 years is 10&nbsp;mg/kg twice daily for most infections, to a maximum of 250&nbsp;mg daily. In otitis media or more severe infections the recommended dose is 15&nbsp;mg/kg twice daily to a maximum of 500&nbsp;mg daily.</p><p>&nbsp;</p><p>The following two tables, divided by age group, serve as a guideline for simplified administration, e.g measuring spoon (5&nbsp;ml) for the 125&nbsp;mg/5&nbsp;ml or the 250&nbsp;mg/5&nbsp;ml multi-dose suspension if provided.</p><p>&nbsp;</p><p><em>Table 3. 10&nbsp;mg/kg dosage for most infections</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:367px"><tbody><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mg) twice daily</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Volume per dose (ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>125&nbsp;mg</p></td><td style="vertical-align:top"><p>250&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>3 to 6 months</p></td><td style="vertical-align:top"><p>40 to 60</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 2 years</p></td><td style="vertical-align:top"><p>60 to 120</p></td><td style="vertical-align:top"><p>2.5 to 5</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>2 to 18 years</p></td><td style="vertical-align:top"><p>125</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2.5</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Table 4. 15 mg/kg dosage for otitis media and more serious infections</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:371px"><tbody><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p><strong>Dose (mg) twice daily</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Volume per dose (ml)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>125&nbsp;mg</p></td><td style="vertical-align:top"><p>250&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>3 to 6 months</p></td><td style="vertical-align:top"><p>60 to 90</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>-</p></td></tr><tr><td style="vertical-align:top"><p>6 months to 2 years</p></td><td style="vertical-align:top"><p>90 to 180</p></td><td style="vertical-align:top"><p>5 to 7.5</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>2 to 18 years</p></td><td style="vertical-align:top"><p>180 to 250</p></td><td style="vertical-align:top"><p>7.5 to 10</p></td><td style="vertical-align:top"><p>2.5 to 5</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established. Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion. Cefuroxime is effectively removed by dialysis.</p><p>&nbsp;</p><p><em>Table 5. Recommended doses for Zinnat in renal impairment</em></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top"><p><strong>T<sub>1/2</sub> (hrs)</strong></p></td><td style="vertical-align:top"><p><strong>Recommended dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge;30 ml/min/1.73 m<sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.4&ndash;2.4</p></td><td style="vertical-align:top"><p>no dose adjustment necessary standard dose of 125 mg to 500 mg given twice daily</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10-29 ml/min/1.73 m<sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>4.6</p></td><td style="vertical-align:top"><p>standard individual dose given every 24 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt;10 ml/min/1.73 m<sup>2 </sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>standard individual dose given every 48 hours</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>During haemodialysis</p></td><td style="vertical-align:top"><p>2&ndash;4</p></td><td style="vertical-align:top"><p>a single additional standard individual dose should be given at the end of each dialysis</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use</p><p>For optimal absorption cefuroxime axetil suspension should be taken with food.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>&nbsp;</p><p>Depending on the dosage, there are other presentations available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1.
	
Patients with known hypersensitivity to cephalosporin antibiotics.

History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>Special care is indicated in patients who have experienced an allergic reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>&nbsp;</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p>&nbsp;</p><p><u>Jarisch-Herxheimer reaction</u></p><p>The Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease.&nbsp; It results directly from the bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete <em>Borrelia burgdorferi</em>.&nbsp; Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease (see section 4.8).</p><p>&nbsp;</p><p><u>Overgrowth of non-susceptible microorganisms</u></p><p>As with other antibiotics, use of cefuroxime axetil may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and <em>Clostridium difficile</em>), which may require interruption of treatment (see section 4.8).</p><p>&nbsp;</p><p>Antibacterial agent&ndash;associated pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for <em>Clostridium difficile</em> should be considered. Medicinal products that inhibit peristalsis should not be given (see section 4.8).</p><p>&nbsp;</p><p><u>Interference with diagnostic tests</u></p><p>The development of a positive Coomb<!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-language:EN-US'><span style='mso-element:
field-begin'></span>SYMBOL 8217\u</span><![endif]--><!--[if supportFields]><span
style='font-size:11.0pt;mso-fareast-language:EN-US'><span style='mso-element:
field-end'></span></span><![endif]-->s Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).</p><p><u>&nbsp;</u></p><p>As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil.</p><p>&nbsp;</p><p><u>Important information about excipients</u></p><p>&nbsp;</p><p>The sucrose content of cefuroxime axetil suspension should be taken into account when treating diabetic patients and appropriate advice provided.</p><p>&nbsp;</p><p>Contains 3&nbsp;g of sucrose per 5&nbsp;ml dose</p><p>Contains 6 mg of propylene glycol (E1520) per 5 ml dose.</p><p>Contains 4.5 mg benzyl alcohol (E1519) per 5 ml dose. Benzyl alcohol may cause allergic reactions</p><p>&nbsp;</p><p>Cefuroxime axetil suspension contains aspartame, which is a source of phenylalanine and so should be used with caution in patients with phenylketonuria. Neither non-clinical nor clinical data are available to assess aspartame use in infants below 12 weeks of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.</p><p>&nbsp;</p><p>Cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.</p><p>&nbsp;</p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenicid is not recommended. Concurrent administration of probenecid significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of cefuroxime.</p><p>&nbsp;</p><p>Concomitant use with oral anticoagulants may give rise to increased INR.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited data from the use of cefuroxime in pregnant women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal development. Zinnat should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p><u>&nbsp;</u></p><p><u>Breastfeeding</u></p><p>Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding after benefit/risk assessment by the physician in charge.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effects of cefuroxime axetil on fertility in humans. Reproductive studies in animals have shown no effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are <em>Candida</em> overgrowth, eosinophilia, headache, dizziness, gastrointestinal disturbances and transient rise in liver enzymes.</p><p>&nbsp;</p><p>The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data (for example from placebo-controlled studies) for calculating incidence were not available. In addition the incidence of adverse reactions associated with cefuroxime axetil may vary according to the indication.</p><p>&nbsp;</p><p>Data from large clinical studies were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e. those occurring at &lt;1/10,000) were mainly determined using post-marketing data and refer to a reporting rate rather than true frequency. Placebo-controlled trial data were not available. Where incidences have been calculated from clinical trial data, these were based on drug-related (investigator assessed) data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for the classification of frequency: very common &sup3; 1/10; common &sup3; 1/100 to &lt; 1/10, uncommon &sup3; 1/1,000 to &lt; 1/100; rare &sup3; 1/10,000 to &lt; 1/1,000; very rare &lt; 1/10,000 and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Infections and infestations</u></p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><em>Candida </em>overgrowth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Clostridium difficile</em> overgrowth</p></td></tr><tr><td style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td><td style="vertical-align:top"><p>eosinophilia</p></td><td style="vertical-align:top"><p>positive Coomb&rsquo;s test<sub>,</sub> thrombocytopenia, leukopenia (sometimes profound)</p></td><td style="vertical-align:top"><p>haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p><u>Immune system disorders</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>drug fever, serum sickness, anaphylaxis, Jarisch-Herxheimer reaction</p></td></tr><tr><td style="vertical-align:top"><p><u>Nervous system disorders</u></p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>headache, dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td><td style="vertical-align:top"><p>diarrhoea, nausea, abdominal pain</p></td><td style="vertical-align:top"><p>vomiting</p></td><td style="vertical-align:top"><p>pseudomembranous colitis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td><td style="vertical-align:top"><p>transient increases of hepatic enzyme levels</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>jaundice (predominantly cholestatic), hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>skin rashes</p></td><td style="vertical-align:top"><p>urticaria, pruritus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (exanthematic necrolysis) (<em>see Immune system disorders</em>), angioneurotic oedema</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Description of selected adverse reactions</em></p><p>Cephalosporins as a class tend to be absorbed onto the surface of red cells membranes and react with antibodies directed against the drug to produce a positive Coombs<!--[if supportFields]><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><span
  style='mso-element:field-begin'></span>SYMBOL 8217\u</span><![endif]--><!--[if supportFields]><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><span
  style='mso-element:field-end'></span></span><![endif]--> test (which can interfere with cross-matching of blood) and very rarely haemolytic anaemia.</p><p>&nbsp;</p><p>Transient rises in serum liver enzymes have been observed which are usually reversible.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Paediatric population</em></p><p>The safety profile for cefuroxime axetil in children is consistent with the profile in adults.</p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Ext: 2317-2356-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Website: www.sfda.gov.sa/npc</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>Serum levels of cefuroxime can be reduced by haemodialysis and peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterials for systemic use, second-generation cephalosporins, ATC code: J01DC02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Cefuroxime axetil undergoes hydrolysis by esterase enzymes to the active antibiotic, cefuroxime.</p><p>Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of resistance</u></p><p><u>&nbsp;</u></p><p>Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hydrolysis by beta-lactamases; &nbsp;including (but not limited to) by extended-spectrum beta-lactamases (ESBLs), and AmpC enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacteria species;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced affinity of penicillin-binding proteins for cefuroxime;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial efflux pumps.</p><p>&nbsp;</p><p>Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime.</p><p>Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.<em> </em></p><p>&nbsp;</p><p><u>Cefuroxime axetil breakpoints</u></p><p><u>&nbsp;</u></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td colspan="2"><p><strong>Breakpoints (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>S</u></p></td><td style="vertical-align:top"><p><u>R</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em> <sup>1, 2</sup></p></td><td style="vertical-align:top"><p>&pound;8</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em> spp.</p></td><td style="vertical-align:top"><p>Note<sup>3</sup></p></td><td style="vertical-align:top"><p>Note<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>A, B, C and G</p></td><td style="vertical-align:top"><p>Note<sup>4</sup></p></td><td style="vertical-align:top"><p>Note<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&pound;0.25</p></td><td style="vertical-align:top"><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&pound;0.125</p></td><td style="vertical-align:top"><p>&gt;4</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&pound;0.125</p></td><td style="vertical-align:top"><p>&gt;1</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>1</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td><td style="vertical-align:top"><p>IE<sup>5</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><sup>1 </sup></strong>The cephalosporin breakpoints for <em>Enterobacteriaceae</em> will detect all clinically important resistance mechanisms (including ESBL and plasmid mediated AmpC). Some strains that produce beta-lactamases are susceptible or intermediate to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as found, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. In many areas, ESBL detection and characterization is recommended or mandatory for infection control purposes.</p><p><sup>2 </sup>Uncomplicated UTI (cystitis) only (see section 4.1).</p><p><sup>3</sup> Susceptibility of staphylococci to cephalosporins is inferred from the methicillin susceptibility except for ceftazidme and cefixime and ceftibuten, which do not have breakpoints and should not be used for staphylococcal infections.</p><p><sup>4</sup> The beta-lactam susceptability of beta-haemolytic streptococci groups A, B, C and G is inferred from the penicillin susceptibility.</p><p><sup>5 </sup>insufficient evidence that the species in question is a good target<sup> </sup>for therapy with the drug. An MIC with a comment but without an accompanying S or R-categorization may be reported.</p></td></tr></tbody></table><p>S=susceptible, R=resistant</p><p>&nbsp;</p><p><u>Microbiological susceptibility</u></p><p><u>&nbsp;</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of cefuroxime axetil in at least some types of infections is questionable.</p><p>&nbsp;</p><p>Cefuroxime is usually active against the following microorganisms <em>in vitro</em>.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Staphylococcus aureus</em> (methicillin susceptible)*<em> </em></p><p><em>Coagulase negative staphylococcus (methicillin susceptible)</em></p><p><em>Streptococcus pyogenes</em></p><p><em>Streptococcus agalactiae </em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Haemophilus influenzae</em></p><p><em>Haemophilus parainfluenzae </em></p><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Spirochaetes:</u></p><p><em>Borrelia burgdorferi</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Microorganisms for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Streptococcus pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>&nbsp;</em><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes </em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis </em></p><p><em>Proteus spp.</em>(other than<em> P. vulgaris) </em></p><p><em>Providencia </em>spp<em>.</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Peptostreptococcus</em> spp.</p><p><em>Propionibacterium</em> spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Fusobacterium </em>spp.</p><p><em>Bacteroides </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant microorganisms </strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter </em>spp.<em> </em></p><p><em>Campylobacter </em>spp.<em> </em></p><p><em>Morganella morganii</em><em> </em></p><p><em>Proteus vulgaris</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia marcescens</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Bacteroides fragilis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia </em>spp.</p><p><em>Mycoplasma</em> spp.</p><p><em>Legionella</em> spp.</p></td></tr></tbody></table><p>&nbsp;*All methicillin-resistant <em>S. aureus</em> are resistant to cefuroxime</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><u>&nbsp;</u></p><p>After oral administration cefuroxime axetil is absorbed from the gastrointestinal tract and rapidly hydrolysed in the intestinal mucosa and blood to release cefuroxime into the circulation. Optimum absorption occurs when it is administered shortly after a meal.</p><p>&nbsp;</p><p>Following administration of cefuroxime axetil tablets peak serum levels (2.1 mcg/ml for a 125 mg dose, 4.1 mcg/ml for a 250 mg dose, 7.0 mcg/ml for a 500 mg dose and 13.6 mcg/ml for a 1000 mg dose) occur approximately 2 to 3 hours after dosing when taken with food. The rate of absorption of cefuroxime from the suspension is reduced compared with the tablets, leading to later, lower peak serum levels and reduced systemic bioavailability (4 to 17% less). Cefuroxime axetil oral suspension was not bioequivalent to cefuroxime axetil tablets when tested in healthy adults and therefore is not substitutable on a milligram-per-milligram basis (see section 4.2).The pharmacokinetics of cefuroxime is linear over the oral dosage range of 125 to 1000&nbsp;mg. No accumulation of cefuroxime occurred following repeat oral doses of 250 to 500&nbsp;mg.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Protein binding has been stated as 33 to 50% depending on the methodology used. Following a single dose of cefuroxime axetil 500 mg tablet to 12 healthy volunteers, the apparent volume of distribution was 50 L (CV%=28%). Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humor. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Cefuroxime is not metabolised.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>The serum half-life is between 1 and 1.5&nbsp;hours. Cefuroxime is excreted by glomerular filtration and tubular secretion. The renal clearance is in the region of 125 to 148 ml/min/1.73 m<sup>2</sup>.</p><p>&nbsp;</p><p><strong><em><u>Special patient populations</u></em></strong></p><p><u>&nbsp;</u></p><p><u>Gender</u></p><p><u>&nbsp;</u></p><p>No differences in the pharmacokinetics of cefuroxime were observed between males and females.</p><p><u>&nbsp;</u></p><p><u>Elderly</u></p><p><u>&nbsp;</u></p><p>No special precaution is necessary in the elderly patients with normal renal function at dosages up to the normal maximum of 1 g per day. Elderly patients are more likely to have decreased renal function; therefore, the dose should be adjusted in accordance with the renal function in the elderly (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Paediatrics</u></p><p><u>&nbsp;</u></p><p>In older infants (aged &gt;3 months) and in children, the pharmacokinetics of cefuroxime are similar to that observed in adults.</p><p>&nbsp;</p><p>There is no clinical trial data available on the use of cefuroxime axetil in children under the age of 3 months.</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>The safety and efficacy of cefuroxime axetil in patients with renal failure have not been established.</p><p>Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function (i.e. C1cr &lt;30&nbsp;ml/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section&nbsp;4.2). Cefuroxime is effectively removed by dialysis.</p><p><strong>&nbsp;</strong></p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>There are no data available for patients with hepatic impairment. Since cefuroxime is primarily eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of cefuroxime.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p><u>&nbsp;</u></p><p>For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with <em>in vivo</em> efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T&gt;MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.</p><p>&nbsp;</p><p>Gamma glutamyl transpeptidase activity in rat urine is inhibited by various cephalosporins, however the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aspartame.</p><p>Xantham gum.</p><p>Acesulfame potassium.</p><p>Povidone K30.</p><p>Stearic acid.</p><p>Sucrose.</p><p>Tutti frutti flavour.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A positive Coombs&#39; test has been reported during treatment with cephalosporins - this</p><p>phenomenon can interfere with cross-matching of blood.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date of the granules is indicated on the packaging.
The reconstituted suspension, when refrigerated between 2 and 8C can be kept for up to 10 days.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p><p>&nbsp;</p><p>The reconstituted suspension must be refrigerated immediately at between 2 and 8&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZINNAT</em> Suspension is supplied in PhEur Type III amber glass bottles with an induction heat seal membrane containing either 125mg/5ml or 250mg/5ml product. Dosing syringes are available with multidose bottles of both strengths.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Constitution/Administration instructions</u></p><p>The bottle should be shaken vigorously before the medication is taken.</p><p>&nbsp;</p><p>The reconstituted suspension when refrigerated between 2 and 8<!--[if supportFields]><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><span style='mso-element:
field-begin'></span>SYMBOL 176\u</span><![endif]--><!--[if supportFields]><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;mso-fareast-language:EN-US'><span
style='mso-element:field-end'></span></span><![endif]-->C can be kept for up to 10 days.</p><p>&nbsp;</p><p>If desired, Zinnat suspension from multidose bottles can be further diluted in cold fruit juices, or milk drinks and should be taken immediately.</p><p>&nbsp;</p><p><u>Directions for reconstituting suspension in multidose bottles</u></p><p><u>&nbsp;</u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the bottle to loosen the content. All the granules should be free-flowing in the bottle. Remove the cap and the heat-seal membrane. If the latter is damaged or not present, the product should be returned to the pharmacist.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add the total amount of cold water as stated on the label or up to the volume line on the cup provided (if supplied). If the water was previously boiled it must be allowed to cool to room temperature before adding. Do not mix Zinnat granules for oral suspension with hot or warm liquids. Cold water must be used to prevent the suspension becoming too thick.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the cap. Allow the bottle to stand to allow the water to fully soak through the granules; this should take about one minute.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert the bottle and shake well (for at least 15 seconds) until all the granules have mixed with the water.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle into an upright position and shake well for one minute until all the granules have blended with the water.</p><p>&nbsp;</p><p>Store the Zinnat suspension immediately at between 2 and 8<sup>o</sup>C (do not freeze) and let it rest for at least one hour before taking the first dose. The reconstituted suspension when refrigerated between 2 and 8<sup>o</sup>C can be kept for up to 10 days.</p><p>&nbsp;</p><p>Always shake the bottle well before taking the medication.</p><p>&nbsp;</p><p>The reconstituted suspension or granules should not be mixed with hot liquids.</p><p>&nbsp;</p><p>Not all presentations are available in every country.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MAH and Manufacturer: 
Glaxo Saudi Arabia Ltd.* 
*member of the GlaxoSmithKline group of companies 

ZINNAT is trademark owned by or licensed to the GSK group of companies 
© 2020 GSK, all rights reserved. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VERSION NUMBER:
UK_V11

DATE OF REVISION OF THE TEXT
02 February 2019

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>